Immune checkpoint inhibitor (nivolumab, pembrolizumab, atezolizumab, durvalumab or combined use of ipilimumab and nivolumab) associated ocular complications Stevens-Johnson syndrome/toxic epidermal necrolysis: An observational cohort, multicenter prospective study
Latest Information Update: 16 Nov 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions
- 16 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress